The first step for pharmacological validation of legumain in AD was obtained using a chemical inhibitor, which reduced the formation of neurotoxic Tau fragments and Aβ accumulation in P301S and 5xFAD mouse models, respectively. Here, MAPT is linked to Alzheimer disease.